Trial record 1 of 1 for:    p'ng loke
Previous Study | Return to List | Next Study

Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova (MUCUS)

This study is currently recruiting participants.
Verified March 2014 by New York University School of Medicine
Sponsor:
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT01433471
First received: September 6, 2011
Last updated: March 7, 2014
Last verified: March 2014

September 6, 2011
March 7, 2014
August 2012
June 2015   (final data collection date for primary outcome measure)
  • Change from baseline of mucus production at 12 weeks and 24 weeks as assessed by histopathology [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline of effector lymphocyte populations (Th1, Th2, Th17, and T-regulatory cells) at 12 and 24 weeks as assessed by flow cytometry of peripheral blood mononuclear cells and isolated leukocytes from pinch biopsies [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline of bacterial composition and attachment at 12 weeks and 24 weeks as assessed by real-time polymerase chain reaction and 454 sequencing of pinch biopsies and stool specimens [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline of gene expression at 12 weeks and 24 weeks as assessed by microarray and real-time polymerase chain reaction analysis of pinch biopsies [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline of mucus production at 12 weeks and 24 weeks as assessed by immunohistochemistry [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline of Th1, Th2, Th17, and T-regulatory cytokine production at 12 and 24 weeks as assessed by flow cytometry of peripheral blood mononuclear cells and pinch biopsies [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline of bacterial composition at 12 weeks and 24 weeks as assessed by real-time polymerase chain reaction and 454 sequencing of pinch biopsies and stool specimens [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline of gene expression at 12 weeks and 24 weeks as assessed by microarray and real-time polymerase chain reaction analysis of pinch biopsies [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01433471 on ClinicalTrials.gov Archive Site
  • Change in Mayo score from baseline at 12 weeks and 24 weeks [ Time Frame: Baseline, 12 weeks, 24 weeks ] [ Designated as safety issue: No ]
    To assess ulcerative colitis disease activity
  • Change from baseline of the Simple Clinical Colitis Activity Index at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks [ Time Frame: Baseline, 2, 4, 6, 8, 10, 14, 16, 18, 20, 22 weeks ] [ Designated as safety issue: No ]
    To assess ulcerative colitis disease activity without requiring endoscopy
Same as current
Not Provided
Not Provided
 
Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova

The purpose of this study is to understand the immune response activated in the human gastrointestinal tract by Trichuris Suis Ova (TSO) in patients with ulcerative colitis.

The concept of helminthic therapy (using worms to treat diseases) is supported by experiments in mouse models as well as several clinical studies. TSO, which are purified eggs from the porcine whipworm Trichuris suis, are being investigated in clinical trials as a potential therapeutic agent for the treatment of active Crohn's disease, relapsing multiple sclerosis, peanut and tree nut allergy, and adults with autistic disorders.

The goal of this study is to understand the immune mechanisms activated in the human gastrointestinal tract by treatment with TSO, which may lead to improvements in the symptoms of ulcerative colitis (UC). TSO have been shown to have a clinical benefit on a subset of patients with UC in a previous randomized placebo-controlled trial (Summers et al. 2005). However, the mechanisms of action of TSO on the intestinal mucosa remain unclear.

We propose an exploratory 24-week mechanistic randomized double-blind placebo-controlled crossover study of TSO in patients with established and active UC to better characterize similarities and differences in the immune mechanisms of the intestinal mucosa in response to TSO. We hypothesize that treatment with TSO will lead to an anti-inflammatory immune response in some individuals with UC through an increase in intestinal mucus production and modulation of Th1, Th2, Th17, and T-regulatory effector lymphocyte populations.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Ulcerative Colitis
Drug: Trichuris suis ova
2,500 eggs by mouth every two weeks for 12 weeks
Other Name: TSO
  • Experimental: Trichuris suis ova followed by placebo
    Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
    Intervention: Drug: Trichuris suis ova
  • Active Comparator: Placebo followed by Trichuris Suis Ova
    Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
    Intervention: Drug: Trichuris suis ova
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
18
December 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects will be outpatients between the ages of 18 and 72.
  • Subjects must have a biopsy-proven diagnosis of ulcerative colitis for greater than three months.
  • There should be evidence of active disease with a total Mayo score of 6 to 10 points (scores range from 0 to 12, with higher scores indicating more severe disease activity).
  • There should be moderate (marked erythema, lack of vascular pattern, friability, erosions) to severe (spontaneous bleeding, ulceration) active disease on colonoscopy (Mayo endoscopic score of at least 2) at time of enrollment.
  • Laboratory inclusion criteria will require a hemoglobin level of >9.0 g/dL, a white blood count between 5,000 and 15,000/μL, a platelet count of >100,000μL, a blood urea nitrogen < 40mg/dL, a serum creatinine of <2.0mg/dL, a total bilirubin < 2.5 mg/dL, and an alkaline phosphatase of <250U/dL.
  • Women will be required to have a negative urine pregnancy test and to practice birth control.
  • The following medications will be allowed and continued throughout the study: Oral or rectal sulfasalazine, mesalamine, or mesalamine derivative (maintenance therapy of > 8 weeks, stable dose of > 4 weeks); Oral corticosteroid (prednisone, prednisolone, or budesonide) at an equivalent dose of a maximum of 40mg daily prednisone (maintenance therapy of >4 weeks, stable dose of > 2 weeks), azathioprine or 6-mercaptopurine (maintenance therapy of > 8 weeks, stable dose of > 4 weeks).
  • Subjects must have the ability to provide informed consent and be willing to keep all scheduled appointments for the duration for the study period.

Exclusion Criteria:

  • Inpatients, pregnant patients, patients with impaired cognition, patients with a history of active substance abuse in the past six months, and children.
  • Patients with a history of bowel surgery in the prior six months or who currently or previously had an ileostomy or colostomy.
  • Patients with active malignancy or treatment with anticancer drugs in the past 5 years, have a history of colorectal cancer or dysplasia, or a history of neoplasm of the gastrointestinal tract.
  • Female patients who are pregnant, breastfeeding, wishing to become pregnant during study participation, or unwilling to use birth control.
  • Patients with white blood count <5,000 or >15,000/mm3; platelet count <150,000 per μl; or iron or vitamin B12 deficiency. Correction of lab exclusion is allowed provided that medical condition is not deemed to put patient at risk and stability of result is sustained for a minimum of 30 days.
  • Patients with stools positive for enteric pathogens, ova, or parasites at Screening
  • Patients with active hepatitis B virus or hepatitis C virus infection or have been exposed to human immunodeficiency virus (HIV).
  • Patients who have received an anti-tumor necrosis factor inhibitor (e.g. infliximab) within 12 weeks prior to Screening
  • Patients who have received antibiotic, antifungal or antiparasitic medication in the last 2 weeks prior to Screening and/or would potentially require this during the study treatment period.
  • Patients with evidence of poor compliance with medical advice and instruction including diet or medication.
  • Patients who are unable or unwilling to swallow study medication suspension.
  • Patients will be excluded if they have previously attempted helminthic therapy.
  • There must not be evidence of fulminant colitis or a Mayo score of greater than 10
  • Patients will be excluded if other clinically significant disease is present that could interfere with protocol compliance or interpretation of the results.
Both
18 Years to 72 Years
No
Contact: Martin J Wolff, M.D. Helminthic.Therapy@nyumc.org
United States
 
NCT01433471
R#11-02470
Yes
New York University School of Medicine
New York University School of Medicine
Not Provided
Principal Investigator: Michael A Poles, M.D., Ph.D. New York University School of Medicine
Principal Investigator: P'ng Loke, Ph.D. New York University School of Medicine
Study Director: Martin J Wolff, M.D. New York University School of Medicine
New York University School of Medicine
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP